Frits van Rhee, M.D., Ph.D., MRCP (UK), FRCPath

vanRheeFrits

 
Professor of Medicine, Director of Developmental and Translational Medicine

Research Interest: Immunotherapy
M.D. Erasmus University of Rotterdam, Netherlands
Ph.D. University of London
Visiting Associate at National Institutes of Health, 8/96 -5/98
Fellow in Hematology & Research Fellow, Hammersmith Hospital & Royal Postgraduate Medical School, London, UK, 6/92 – 8/96
Registrar Fellow in Hematology, John Radcliffe University Hospital, Oxford, UK, 2/91 – 5/92
Registrar Fellow in Hematology, University Hospital, Nottingham, UK, 2/90 – 1/91
Residencies from 8/86 to 2/90 at Queen Elizabeth Hospital in Gateshead, UK and Macclesfiedl District General Hospital, Macclesfield, UK

Selected Publications:

Katie Stone , Emily Woods, Susann M. Szmania, Owen W. Stephens, Tarun K. Garg, Bart Barlogie, John D. Shaughnessy, Jr.,, Brett Hall, Manjula Reddy, Antje Hoering, Emily Hansen, Frits van Rhee. Interleukin-6 Receptor Polymorphism Is Prevalent in HIV negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels.

Razelle Kurzrock, Peter M. Voorhees, Corey Casper et al.  A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease.  Clin Cancer Research 2013; 19:3659-3670

Tarun K. Garg, Susann M. Szmania, Junaid A. Khan,Antje Hoering,Paul A. Malbrough, Amberly Moreno-Bost,Amy D.Greenway,  Joshuah D. Lingo,  Xin Li, Shmuel Yaccoby,  Larry J. Suva,  Brian Storrie,Guido Tricot,Dario Campana,John D. Shaughnessy Jr.,  Bijay P. Nair,  William T. Bellamy,  Joshua Epstein, Bart Barlogie,and Frits van Rhee. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 2012;97(9):1348-1356. doi:10.3324/haematol.2011.056747

Natalia Lapteva, April G. Durett, Jiali Sun, Lisa A Rollins, Leslie L Juye, Jian Fang, Varada Dandekar,Zhuyong Mei, Kimberley Jackson, Juan Vera, Jun Ando, Minhtran Ngo, Elaine Coustan-Smith, Dario Campana, Susann Szmania, Tarun Garg, Amberly Moreno-Bost, Frits van Rhee, Adrian P Gee, and Cliona M. Rooney.  Large -scale ex vivo enpansion and characterization of natural killer cells for clinical applications. Cytotherapy, 2012; 14: 1131-1143

Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophon du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010;28:1209-14. PMID: 20085933.

van Rhee F. Turning up the heat on myeloma. Blood. 2009;114:3721-5. PMID: 19875523.

van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8:2616-24. PMID: 19723891.

Shi J, Tricot G, Szmania S, Rosen N, Garg T, Malaviarachchi P, Moreno A, Dupont B, Hsu K, Baxter-Lowe L, Cottler-Fox M, Shaughnessy J, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Brit J Haematol. 2008; 143: 641-653. PMID: 18950462.

van Rhee F, Dhodapkar M, Shaughnessy JD, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath J, Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade later. Blood. 2008;112:1035-8. PMID: 18502827.

Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Barlogie B, van Rhee F. Bortezomib down regulates the cell surface expression of HLA class I and enhances natural killer cell mediated lysis of myeloma. Blood. 2008;111:1309-17. PMID: 17947507.

Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Huang Y, Moreno A, Thuro B, Mellenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007;30:847-54. PMID: 18049337.

van Rhee F. Idiotype vaccination strategies in myeloma: How to overcome a dysfunctional immune system. Clin Cancer Res. 2007;13:1353-55. PMID: 17332275.

van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy Jr JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110: 827-32. PMID: 17416735.

Batchu RB, Moreno AM, Szmania SM, Bennet GW, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot, G, van Rhee F. Protein Transduction of Dendritic Cells for NY-ESO-1 Based Immunotherapy of Myeloma. Cancer Res. 2005;65:10041-9. PMID: 16267030.

van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy JD, Tricot G. NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939-44. PMID: 15671442.. Batchu RB, Moreno AM, Gupta SK, Szmania S, Zhan F, Spagnoli GC, C, Barlogie B, Tricot, G, van Rhee F. High Level expression in the cancer/testis antigen NY-ESO-1 and human GM-CSF in dendritic cells with a bicistronic retroviral vector. Human Gene Therapy 2003;14:1333-45.

Batchu RB, Moreno AM, Szmania S, Gupta SK, Zhan F, Rosen N, Kozlowski M, Spencer T, Spagnoli GC, Shaughnessy J, Barlogie B, Tricot G, van Rhee F. High level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector. Hum Gene Ther. 2003;14:1333-45. PMID: 14503968.

Musk P, Szmania S, Galloway AT, Johnson K, Scott A, Guttman S, Bridges K, Bruorton M, Gatlin J, Garcia JV, Lamb L, Chiang KY, Spencer T, Henslee_Downey J, van Rhee F. In vitro generation of Epstein Barr virus-specific cytotoxic T cells in patients receiving haplo-identical allogeneic stem cell transplantation. J Immunother. 2001;24:312-22. PMID: 11565833.

Szmania S, Galloway A, Bruorton M, Musk P, Aubert G, Arthur A, Pyle H, Hensel N, Ta N, Lamb L Jr, Dodi T, Madrigal A, Barrett J, Henslee-Downey PJ, van Rhee F. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood. 2001;98:505-12. PMID: 11468143.

van Rhee F, Jiang YZ ,Vigue F, Kirby M, Mavroudis D, Hensel NF, Agarwala V, Clave E, Childs R, Raptis A, Sloand E, Carter C, Read EJ, Barrett AJ. Human G-CSF mobilized CD34 positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. Brit J Haematol. 1999;105:1014-24. PMID: 10554815.

van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and lymphoblastic leukemias. Blood. 1996;87:5213-7. PMID: 8652835.

van Rhee F, Lin Feng, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett AJ, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic Bone Marrow Transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377-83.